Biologicals are often thought to increase the risk of infection. A recent review shows that the risk of serious infection in patients with rheumatoid arthritis being treated with biologicals (standard dose) is only mildly elevated compared with those who are treated with conventional DMARDs only (odds ratio: 1.3). If biologicals are used at a lower dosage, e.g. tapering studies, the risk of serious infection does not seem to be increased. Alertness for infection in these patients, dose tapering and preventive measures such as vaccination, patient education and tuberculosis screening may potentially further reduce this serious side effect of biologicals
Patients with rheumatoid arthritis and other immune-mediated inflammatory diseases are at higher ris...
OBJECTIVES: The aims of this study were to define the risk of serious bacterial infections in patie...
Background: This research describes the incidence and factors associated with opportunistic infectio...
Item does not contain fulltextBiologicals are often thought to increase the risk of infection. A rec...
: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the management of ...
Immunomodulatory therapy for rheumatoid arthritis (RA) carries risk for infectious complications. Un...
Purpose of review The purpose of this review is to provide an update concerning recent advances in t...
While initial researches documented that Rheumatoid Arthritis (RA) patients who took biologic agents...
Background. Biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic (ts) D...
Patients with rheumatoid arthritis (RA) has an increased infections risk and morbidity and mortality...
The aims of this study were to define the risk of serious bacterial infections in patients receiving...
Long-term extension studies and observational drug registers have revealed an increased risk of seri...
Background Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and p...
Patients with inflammatory rheumatic conditions have an increased risk of infection. While this coul...
Objectives To compare the incidence of serious infection (SI) across biologic drugs used to treat rh...
Patients with rheumatoid arthritis and other immune-mediated inflammatory diseases are at higher ris...
OBJECTIVES: The aims of this study were to define the risk of serious bacterial infections in patie...
Background: This research describes the incidence and factors associated with opportunistic infectio...
Item does not contain fulltextBiologicals are often thought to increase the risk of infection. A rec...
: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the management of ...
Immunomodulatory therapy for rheumatoid arthritis (RA) carries risk for infectious complications. Un...
Purpose of review The purpose of this review is to provide an update concerning recent advances in t...
While initial researches documented that Rheumatoid Arthritis (RA) patients who took biologic agents...
Background. Biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic (ts) D...
Patients with rheumatoid arthritis (RA) has an increased infections risk and morbidity and mortality...
The aims of this study were to define the risk of serious bacterial infections in patients receiving...
Long-term extension studies and observational drug registers have revealed an increased risk of seri...
Background Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and p...
Patients with inflammatory rheumatic conditions have an increased risk of infection. While this coul...
Objectives To compare the incidence of serious infection (SI) across biologic drugs used to treat rh...
Patients with rheumatoid arthritis and other immune-mediated inflammatory diseases are at higher ris...
OBJECTIVES: The aims of this study were to define the risk of serious bacterial infections in patie...
Background: This research describes the incidence and factors associated with opportunistic infectio...